scholarly article | Q13442814 |
P50 | author | CS Chim | Q64761563 |
P2093 | author name string | George A Calin | |
Dong-Yan Jin | |||
Shaji Kumar | |||
Wee-Joo Chng | |||
Ming-Wai Poon | |||
Kam-Leung Siu | |||
Zhenhai Li | |||
P2860 | cites work | Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study | Q24653006 |
Worms gang up on bacteria | Q27860588 | ||
CpG islands in vertebrate genomes | Q27861045 | ||
Long non-coding RNAs in normal and malignant hematopoiesis | Q28070169 | ||
Long non-coding RNAs: insights into functions | Q28131764 | ||
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group | Q28207984 | ||
Hypermethylation of gene promoters in hematological neoplasia | Q28216777 | ||
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma | Q28249838 | ||
The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium | Q28585080 | ||
A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression | Q29614326 | ||
Evolution and functions of long noncoding RNAs | Q29614331 | ||
DNA methylation in health and disease | Q30659938 | ||
International staging system for multiple myeloma | Q34408882 | ||
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. | Q34413764 | ||
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Q34450381 | ||
Structure, function and evolution of CpG island promoters | Q35541032 | ||
Epigenomics: beyond CpG islands. | Q35778671 | ||
Myeloma as a model for the process of metastasis: implications for therapy | Q36079800 | ||
Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. | Q36094729 | ||
Long non-coding RNAs and cancer: a new frontier of translational research? | Q36208103 | ||
Epigenetic inactivation of the MIR129-2 in hematological malignancies. | Q36621405 | ||
The Impact of DNA Methylation in Hematopoietic Malignancies | Q36724810 | ||
CpG island hypermethylation of tumor suppressor microRNAs in human cancer | Q36854202 | ||
A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis | Q37064899 | ||
Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. | Q37343917 | ||
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. | Q37400912 | ||
Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway | Q37424922 | ||
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management | Q37623809 | ||
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. | Q37696142 | ||
Pathogenesis of myeloma | Q37831905 | ||
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer | Q37921080 | ||
The genetic architecture of multiple myeloma. | Q38001913 | ||
Interplay between the cancer genome and epigenome | Q38094260 | ||
SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway | Q38344554 | ||
DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma | Q38595057 | ||
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Q38832525 | ||
An Extended Least Squares Method for Aliasing-Resistant Vector Velocity Estimation | Q39205060 | ||
LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma | Q41169814 | ||
Epigenetic inactivation of the MIR34B/C in multiple myeloma. | Q43422429 | ||
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Q47283493 | ||
Long Non-Coding RNAs in Multiple Myeloma | Q48124218 | ||
Molecular detection of minimal residual disease in multiple myeloma. | Q48371783 | ||
Epigenetic silencing of EVL/miR-342 in multiple myeloma. | Q49838762 | ||
Long Noncoding RNA CRNDE Promotes Multiple Myeloma Cell Growth by Suppressing miR-451. | Q50853841 | ||
Epigenetic silencing of MIR203 in multiple myeloma. | Q53285292 | ||
RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNFα in the microenvironment. | Q54206324 | ||
Epigenetic silencing of LPP/miR-28 in multiple myeloma. | Q55263293 | ||
Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma | Q73229221 | ||
DNA methylation changes in multiple myeloma | Q80468799 | ||
P304 | page(s) | 403 | |
P577 | publication date | 2020-08-25 | |
P1433 | published in | Cancer Cell International | Q1829859 |
P1476 | title | Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination | |
P478 | volume | 20 |
Search more.